Pre-market hot trades in US stocks: Workday pre-market down 7.17%; Intuit pre-market down 5.10%

Pre-market Hot Trades in US Stocks

Workday fell 7.17% in pre-market trading. There has been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news

Intuit fell 5.10% in pre-market trading. Based on recent key news:

1. On July 14, Rosen Law Firm filed a securities fraud class action against Intuit, accusing it of making misleading statements between August 22, 2025, and May 20, 2026, leading to stock price fluctuations. This lawsuit may negatively impact the company's reputation and stock price.

2. On July 14, market analysis showed that although Intuit currently has a "Moderate Buy" rating, top analysts believe there are five stocks with greater investment value, which may affect investor confidence.

3. On July 11, Robbins LLP announced its success in a shareholder rights lawsuit, which, although not directly related to Intuit, may raise investor concerns about potential legal risks for Intuit. Increased market attention to Intuit's legal risks affects its stock price.

Top Gainers in Pre-market US Stocks

NextCure rose 373.84% in pre-market trading. Based on recent key news:

1. On July 14, NextCure announced a merger with Avere Therapeutics, and will operate under the Avere Therapeutics name post-merger. This news drove NextCure's stock price up 93% in pre-market trading. Source: GlobeNewswire

2. On July 14, NextCure announced it secured $320 million in private financing to develop AVR-001, an experimental drug for inflammatory diseases. This financing plan has boosted market confidence in the company's future development. Source: GlobeNewswire

3. On July 14, Avere plans to initiate a mid-stage psoriasis trial in early 2027, with data expected to be released in the first half of 2028. This plan demonstrates the company's positive progress in R&D, further boosting investor confidence. Source: GlobeNewswire The biotechnology industry has seen frequent merger activities recently.

Shuttle Pharmaceuticals rose 47.90% in pre-market trading. Based on recent news,

1. On July 13, HRT Financial LP increased its direct holdings in Shuttle Pharmaceuticals to 61,271 shares. HRT Financial purchased 8,997 shares on the open market at prices ranging from $3.11 to $3.38 per share. Following this news, market demand for the stock significantly increased, driving the stock price up sharply On July 13, HRT Financial reported in Form 3 that its stake in Shuttle Pharmaceuticals reached 10%. As of July 9, HRT Financial directly held 60,540 shares of common stock. This increase in shareholding was interpreted by the market as confidence in the company's prospects, further driving up the stock price. The market holds an optimistic view of the company's future, pushing the stock price higher.

Picard Medical rose 36.91% in pre-market trading. Based on recent news,

1. On July 14, Picard Medical's stock price surged by 36.91%, primarily due to the company announcing a significant strategic partnership agreement. This agreement is expected to significantly enhance the company's market share and profitability, and investors reacted positively, driving the stock price up sharply.

2. On July 13, Picard Medical released its latest quarterly financial report, showing that both revenue and profit exceeded market expectations. The report indicated that the company's sales in several key markets achieved double-digit growth, further boosting investor confidence.

3. On July 12, a well-known analyst upgraded the rating for Picard Medical and significantly raised the target price. The analyst pointed out that the company has excelled in technological innovation and market expansion, with substantial growth potential in the future, and this rating adjustment triggered a positive market response. The healthcare industry has performed strongly recently, and investor sentiment is high